Should There Be a Different Cardiovascular Prevention Polypill Strategy for Women and Men?
- First Online:
- 51 Downloads
The concept of a polypill for cardiovascular disease prevention has attracted widespread attention since Wald and Law’s seminal paper in 2003. The authors estimated > 80% reduction in coronary heart disease and stroke deaths through mass application of a polypill in people aged 55 years and older. Although their proposition has been subject to criticisms and heated debate regarding side effects, efficacy, and appropriateness of the intervention, few have discussed the differential risks and benefits of a polypill for women and men and whether sex-specific polypill strategies should be developed. In this review, we discuss the benefits and drawbacks of sex-specific polypill strategies by evaluating the published literature regarding 1) sex differences in cardiovascular risk and risk reduction, 2) risks and benefits of a polypill in women compared to men, 3) anticipated hurdles to implementing a polypill strategy, 4) special considerations related to low- and middle-income country settings, and 5) potential sex-specific polypill strategies.
KeywordsPolypill Women Cardiovascular disease Prevention
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. WHO-Wellcome Trust Meet. Rep. 1–3. Geneva: World Health Organization; 2002.Google Scholar
- 6.Smith, R. The most important BMJ in 50 years? BMJ. 2003;326(7404).Google Scholar
- 9.•• Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet 2009;373:1341–51. The Indian Polypcap Study (TIPS) was the first phase 2 polypill study published, reflecting the global interest in a polypill strategy. PubMedCrossRefGoogle Scholar
- 11.UMPIRE—Use of a Multidrug Pill In Reducing Cardiovascular Events. ClinicalTrials.gov Identifier: NCT01057537. Available at: http://clinicaltrials.gov/ct2/show/NCT01057537?term=umpire&rank=1. Accessed 27 November 2010.
- 15.Marma AK, Berry JD, Ning H, Persell SD, Lloyd-Jones DM. Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcomes. 2010;3:8–14.PubMedCrossRefGoogle Scholar
- 18.Calderon-Margalit R, Schwartz SM, Wellons MF, et al. Prospective association of serum androgens and sex hormone-binding globulin with subclinical cardiovascular disease in young adult women: the “Coronary Artery Risk Development in Young Adults” women’s study. J Clin Endocrinol Metab. 2010;95:4424–31.PubMedCrossRefGoogle Scholar
- 21.• Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60. These data from the Antithrombotic Trialists’ Collaboration reflect the most up-to-date evaluation of the risks and benefits of aspirin in women and men in the prevention of cardiovascular disease. PubMedCrossRefGoogle Scholar
- 29.Czernichow S, Zanchetti A, Turnbull F, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 2010:[Epub ahead of print].Google Scholar
- 38.Niens LM, Cameron A, Van de Poel E, Ewen M, Brouwer WB, Laing R. Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010;7.Google Scholar
- 39.•• van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010;10:25. This article, based on data from the World Health Organization/Health Action International database, provides the most up-to-date, comprehensive perspective on cardiovascular drug costs around the world, including in LMICs. PubMedCrossRefGoogle Scholar
- 41.Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010:[Epub ahead of print].Google Scholar
- 48.Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med 2010.Google Scholar
- 51.World Population Highlights: Key findings from PRB’s 2009 world population data sheet. Population Bulletin 64, no. 3 (2009).Google Scholar
- 52.Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396–404.Google Scholar